Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials

Abstract

A pooled analysis was conducted of 1257 toddlers who received a fourth dose of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) or Hib conjugate vaccine (Hib polysaccharide conjugated to N. meningitidis outer membrane protein) coadministered with measles-mumps-rubella (MMR) and varicella (VAR) vaccines (NCT00134719/NCT00289783). Noninferiority of immunological responses to MMR and VAR was demonstrated between groups and incidences of MMR- and VAR-specific solicited symptoms were similar, indicating that HibMenCY-TT can be coadministered with MMR and VAR.

Figure 1. Difference between the HibMenCY-TT and Hib-OMP groups in percentage of subjects who seroconverted for measles, mumps, and varicella and with a seroresponse to rubella 42 d post-fourth dose of HibMenCY-TT/Hib-OMP in the Australian study (Aus), US immunogenicity cohort (US), and pooled analysis (Pooled) (ATP cohorts for immunogenicity; subjects who were seronegative at baseline). Limits represent 95% confidence intervals. Footnote: Anti-measles seroconversion: post-vaccination antibody concentration ≥ 150 mIU/mL in initially seronegative subjects (< 150 mIU/mL); anti-mumps seroconversion: post-vaccination antibody titer ≥ 28 ED₅₀ in initially seronegative subjects (< 28 ED₅₀); anti-rubella seroresponse: post-vaccination antibody concentration ≥ 10 IU/mL in initially seronegative subjects (< 4 IU/mL); anti-varicella seroconversion: post-vaccination antibody titer ≥ 1:5 in initially seronegative subjects (< 1:5); * limit of non-inferiority varicella; ** limit of non-inferiority measles, mumps, and rubella.